Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mutations01:39

Mutations

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TDP-43-dependent mis-splicing of KCNQ2 triggers intrinsic neuronal hyperexcitability in ALS/FTD.

Nature neuroscience·2025
Same author

Emerging therapies in idiopathic inflammatory myopathies.

Journal of neuromuscular diseases·2025
Same author

Palmitoyl-Protein Thioesterase 1 (PPT1) Protein, Linked to Neuronal Ceroid Lipofuscinosis 1, Is a Major Constituent of Ageing-Related Human Neuronal Lipofuscin.

Neuropathology and applied neurobiology·2025
Same author

Cell-cell communication dysregulation in tuberous sclerosis complex cortical tubers and focal cortical dysplasia.

Acta neuropathologica communications·2025
Same author

SpliPath enhances disease gene discovery in case-control analyses of rare splice-altering genetic variants.

Cell reports methods·2025
Same author

A clinical and genotype-phenotype analysis of MACF1 variants.

American journal of human genetics·2025
Same journal

Aquatic training improves muscle strength and functional mobility in adults with myotonic dystrophy type 1: a pilot randomized trial.

Neuromuscular disorders : NMD·2026
Same journal

Severe dilated cardiomyopathy in females with dystrophinopathy : a case series of nine patients.

Neuromuscular disorders : NMD·2026
Same journal

A portrait of facioscapulohumeral muscular dystrophy through history: past milestones and future challenges on the road to understanding and treatment.

Neuromuscular disorders : NMD·2026
Same journal

Systematic review of outcome measures in facioscapulohumeral dystrophy (FSHD): validated, usable, and feasible tools for assessing function, performance, and strength.

Neuromuscular disorders : NMD·2026
Same journal

Longitudinal functional trajectories in Duchenne muscular dystrophy: outcome-specific patterns from a registry-based modelling study.

Neuromuscular disorders : NMD·2026
Same journal

HACD1-related congenital myopathy skeletal muscle MRI findings in a Brazilian cohort.

Neuromuscular disorders : NMD·2026
See all related articles

Related Experiment Video

Updated: Jul 1, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

TPM2 mutation

Almuth Brandis, Eleonora Aronica, Hans H Goebel

    Neuromuscular Disorders : NMD
    |September 16, 2008
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Yeast As a Chassis for Developing Functional Assays to Study Human P53
    14:57

    Yeast As a Chassis for Developing Functional Assays to Study Human P53

    Published on: August 4, 2019

    Related Experiment Videos

    Last Updated: Jul 1, 2026

    Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
    08:45

    Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

    Published on: July 17, 2020

    Yeast As a Chassis for Developing Functional Assays to Study Human P53
    14:57

    Yeast As a Chassis for Developing Functional Assays to Study Human P53

    Published on: August 4, 2019